BSX Stock Analysis: Boston Scientific | NYSE
Medical Devices | NYSE, USA | Market Cap: 61.965m USD | 12M Return: -57.6% | US1011371077 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 803M
EPS Trend: 98.2%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Boston Scientific Corporation is a global medical device company that develops, manufactures, and markets products across two operating segments: MedSurg and Cardiovascular. Its portfolio spans gastrointestinal, urological, neurological, and pain management therapies, as well as a broad range of cardiac and peripheral vascular devices. Notable offerings include the WATCHMAN FLX left atrial appendage closure device, spinal cord stimulators, deep brain stimulation systems, and single-use scopes for endoscopic procedures. The company also serves oncology and rhythm management markets through diagnostic, implantable, and remote monitoring technologies.
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific has been listed on the NYSE since 1992 and is classified within the Health Care Equipment sub-industry. The medical device sector is characterized by significant investment in research and development, lengthy regulatory approval cycles, and a mix of capital equipment sales combined with recurring revenue from consumables, implants, and ongoing patient monitoring services.
- WATCHMAN FLX adoption accelerates cardiovascular segment revenue growth
- Axonics acquisition expands neuromodulation portfolio and recurring revenue base
- China volume-based procurement pricing pressure compresses international margins
| Net Income: 3.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.51 > 1.0 |
| NWC/Revenue: 10.36% < 20% (prev 13.99%; Δ -3.63% < -1%) |
| CFO/TA 0.09 > 3% & CFO 4.23b > Net Income 3.49b |
| Net Debt (11.5b) to EBITDA (5.46b): 2.10 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.45b) vs 12m ago -2.91% < -2% |
| Gross Margin: 70.37% > 18% (prev 65.05%; Δ 5.32% > 0.5%) |
| Asset Turnover: 47.79% > 50% (prev 45.31%; Δ 2.48% > 0%) |
| Interest Coverage Ratio: 10.72 > 6 (EBIT TTM 4.03b / Interest Expense TTM 376.0m) |
| A: 0.05 (Total Current Assets 8.16b - Total Current Liabilities 5.98b) / Total Assets 45.5b |
| B: 0.18 (Retained Earnings 8.40b / Total Assets 45.5b) |
| C: 0.09 (EBIT TTM 4.03b / Avg Total Assets 44.1b) |
| D: 1.31 (Book Value of Equity 25.6b / Total Liabilities 19.6b) |
| Altman-Z'' = 2.91 = A |
| DSRI: 1.01 (Receivables 3.11b/2.83b, Revenue 21.1b/19.4b) |
| GMI: 0.92 (GM 65.05% / 70.37%) |
| AQI: 1.02 (AQ_t 0.73 / AQ_t-1 0.71) |
| SGI: 1.09 (Revenue 21.1b / 19.4b) |
| TATA: -0.02 (NI 3.49b - CFO 4.23b) / TA 45.5b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of November 13, 2026, the stock is trading at USD 44.20 with a total of 11,503,335 shares traded. Over the past week, the price has changed by -0.99%, over one month by +0.82%, over three months by -14.04% and over the past year by -57.55%.
Current recommended Stop Loss: 40.90 (which is 7.5% or 1.9 ATR below the current price).
Boston Scientific has received a consensus analysts rating of 4.10. Therefore, it is recommended to buy BSX.
- StrongBuy: 14
- Buy: 6
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49.6 | 12.2% |
P/E Trailing = 18.038
P/E Forward = 13.7741
P/S = 2.9409
P/B = 2.4177
P/EG = 0.719
Revenue TTM = 21.1b USD
EBIT TTM = 4.03b USD
EBITDA TTM = 5.46b USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 12.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.0m
Net Debt = 11.5b USD (calculated: Debt 12.1b - CCE 609.0m)
Enterprise Value = 73.4b USD (62.0b + Debt 12.1b - CCE 609.0m)
Interest Coverage Ratio = 10.72 (Ebit TTM 4.03b / Interest Expense TTM 376.0m)
EV/FCF = 22.05x (Enterprise Value 73.4b / FCF TTM 3.33b)
FCF Yield = 4.54% (FCF TTM 3.33b / Enterprise Value 73.4b)
FCF Margin = 15.81% (FCF TTM 3.33b / Revenue TTM 21.1b)
Net Margin = 16.56% (Net Income TTM 3.49b / Revenue TTM 21.1b)
Gross Margin = 70.37% ((Revenue TTM 21.1b - Cost of Revenue TTM 6.24b) / Revenue TTM)
Gross Margin QoQ = 66.72% (prev 70.71%)
Tobins Q-Ratio = 1.62 (Enterprise Value 73.4b / Total Assets 45.5b)
Interest Expense / Debt = 3.11% (Interest Expense 376.0m / Debt 12.1b)
Taxrate = 4.46% (163.0m / 3.65b)
NOPAT = 3.85b (EBIT 4.03b * (1 - 4.46%))
Current Ratio = 1.36 (Total Current Assets 8.16b / Total Current Liabilities 5.98b)
Debt / Equity = 0.47 (Debt 12.1b / totalStockholderEquity, last quarter 25.6b)
Debt / EBITDA = 2.10 (Net Debt 11.5b / EBITDA 5.46b)
Debt / FCF = 3.44 (Net Debt 11.5b / FCF TTM 3.33b)
Total Stockholder Equity = 25.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.92% (Net Income 3.49b / Total Assets 45.5b)
RoE = 13.87% (Net Income TTM 3.49b / Total Stockholder Equity 25.2b)
RoCE = 11.21% (EBIT 4.03b / Capital Employed (Equity 25.2b + L.T.Debt 10.8b))
RoIC = 9.65% (NOPAT 3.85b / Invested Capital 39.9b)
WACC = 6.35% (E(62.0b)/V(74.0b) * Re(7.01%) + D(12.1b)/V(74.0b) * Rd(3.11%) * (1-Tc(0.04)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -38.32 | Cagr: -0.97%
[DCF] Terminal Value 73.67% ; FCFF base≈3.51b ; Y1≈3.17b ; Y5≈2.73b
[DCF] Fair Price = 22.08 (EV 43.5b - Net Debt 11.5b = Equity 32.0b / Shares 1.45b; r=8.35% [WACC [floored]]; 5y FCF grow -11.76% → 2.50% )
EPS Correlation: 98.22 | EPS CAGR: 19.33% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.97 | Revenue CAGR: 17.09% | SUE: 1.36 | # QB: 2
EPS current Quarter (2027-03-31): EPS=0.74 | Chg30d=-6.85% | Revisions=-77% | Analysts=17
EPS current Year (2026-12-31): EPS=3.17 | Chg30d=-2.74% | Revisions=-77% | GrowthEPS=+3.6% | GrowthRev=+4.5%
EPS next Year (2027-12-31): EPS=3.13 | Chg30d=-8.01% | Revisions=-88% | GrowthEPS=-1.3% | GrowthRev=-0.5%
[Analyst] Revisions Ratio: -91% (up=1, down=51)